Mechanistic insights such as these would inform targeted trial designs and treatment strategies in a manner that is consonant with the growing trend in the field to devolve into molecularly defined care and to achieve improved outcomes in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.